{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-032093","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.051069+00:00","generated_at":"2026-05-14T22:00:13.919898+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ginkgo Bioworks Q1 revenue $19M (-49% YoY); narrows net loss; cash burn guidance reaffirmed","bullets":["Revenue $19M, down 49% YoY; prior year included $7M non-cash deferred revenue release; adjusted EBITDA -$42M.","GAAP net loss from continuing ops -$76M (vs -$83M prior year); operating cash burn trajectory reaffirmed.","Completed Biosecurity divestiture on April 3, 2026; results presented as discontinued ops.","Cash, cash equivalents and marketable securities $373M as of March 31, 2026.","Reaffirms FY 2026 total cash burn guidance of $(150)-$(125) million."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-032093","json":"https://secwatch.observer/filing/0001628280-26-032093.json","markdown":"https://secwatch.observer/filing/0001628280-26-032093.md","text":"https://secwatch.observer/filing/0001628280-26-032093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828026032093/0001628280-26-032093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828026032093/dna-20260507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T22:00:13.919898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7251a4716bd83646f951c2ec95dabce82366d300","claim":"Ginkgo Bioworks Holdings, Inc. reported the first quarter ended March 31, 2026 results: revenue $19 million, net income $(76) million. Guidance reaffirmed.","evidence_excerpt":"• First quarter 2026 Revenue of $19 million compared to $38 million in the comparable prior year period, a decrease of 49%. As previously reported, the first quarter of 2025 benefited from $7 million of non-cash revenue from previously announced release of deferred revenue relating to the mutual termination of a customer agreement. Excluding this non-cash deferred revenue release, first quarter 2026 Revenue of $19 million, down from $31 million in the comparable prior year period, a decrease of 37%. The decrease in revenue is primarily attributed to ongoing program rationalization as part of our restructuring activities. • First quarter 2026 GAAP net loss from continuing operations of $(76) million, compared to $(83) million in the comparable prior year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828026032093/0001628280-26-032093-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Revenue","value":"$19 million"},{"label":"Net income","value":"$(76) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}